Latest Xenon Pharmaceuticals Inc. Stories
CARLSBAD, Calif. and VANCOUVER, Canada, Nov. 16, 2010 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Xenon Pharmaceuticals Inc.
VANCOUVER, Canada, Aug. 17 /PRNewswire/ -- Xenon Pharmaceuticals Inc. announced today that it has initiated a phase 2 clinical trial evaluating its novel topical XEN402 therapy for the treatment of PHN.
VANCOUVER, May 17 /PRNewswire/ -- Xenon Pharmaceuticals Inc. is pleased to announce today that it has appointed Tarek S. Mansour as Executive Vice President, Research and Development. "We are delighted to welcome Tarek to the Xenon team," commented Simon Pimstone, Xenon's President and CEO.
VANCOUVER, British Columbia, June 17 /PRNewswire/ -- Xenon Pharmaceuticals Inc., a drug discovery and development company, is pleased to announce today that it has been awarded the Promising Early Stage Company of the Year Award by BIOTECanada in the Health category for 2008.
- A hairdresser.